journal article·2019-12-04Open access

Hsa_Circ_0001206 is downregulated and inhibits cell proliferation, migration and invasion in prostate cancer

Zhenyu Song, Zhiyuan Zhuo, Zhe Ma, Chuansheng Hou, Gang Chen, Guoxiong Xu

Abstract

Our study is to explore the expression profiles and potential functions of circRNAs in prostate cancer (PCa). A total of 95 circRNAs and 830 mRNAs were screened to be significantly differentially expressed in PCa tissues by microarrays. Co-expression and competitive endogenous RNA (ceRNA) network were constructed to reveal the potential regulatory mechanisms of circRNAs. Three circRNAs, hsa_circ_0001206, hsa_circ_0001633, and hsa_circ_0009061 were validated to be down-regulated in PCa by quantitative real-time PCR (qRT-PCR) and hsa_circ_0001206 as well as hsa_circ_0009061 was significantly associated with clinical features of PCa patients. Meanwhile, Receiver Operating Characteristic (ROC) curves showed their good diagnostic value as biomarkers for PCa. The down-regulation of hsa_circ_001206 was partly because of the regulation of DExH-Box Helicase 9 (DHX9). Moreover, overexpression of hsa_circ_0001206 inhibited PCa cell proliferation, migration, and invasion in vitro and prevented tumor growth in vivo. Dual-luciferase reporter assays showed hsa_circ_0001206 could directly bind to miR-1285-5p. The expression of Smad4, a well-known suppressive gene in PCa, can be increased by overexpression of hsa_circ_0001206 and this effect could be partly reversed by co-transfection of miR-1285-5p mimic. The study revealed expression profiles and potential functions of circRNAs and demonstrated hsa_circ_0001206 played a suppressive role in the pathogenesis of PCa.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Circular RNAs in diseases · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Urology, Jinshan Hospital of Fudan University

Center Laboratory, Jinshan Hospital, Fudan University

Funding

Natural Science Foundation of Shanghai

References (48)

Show source-provided references
1. 10.3322/caac.2155110.3322/caac.21551 ↗
2. 10.1038/pcan.2009.6310.1038/pcan.2009.63 ↗
3. 10.1093/annonc/mds36210.1093/annonc/mds362 ↗
4. 10.1001/jama.2014.208510.1001/jama.2014.2085 ↗
5. 10.1093/jnci/djp00110.1093/jnci/djp001 ↗
6. 10.1080/15476286.2015.102027110.1080/15476286.2015.1020271 ↗
7. 10.1038/nature1199310.1038/nature11993 ↗
8. 10.1038/nature1192810.1038/nature11928 ↗
9. 10.1038/ncomms1121510.1038/ncomms11215 ↗
10. 10.1371/journal.pone.014121410.1371/journal.pone.0141214 ↗
11. 10.1373/clinchem.2014.23043310.1373/clinchem.2014.230433 ↗
12. 10.1155/2016/157949010.1155/2016/1579490 ↗
13. 10.1038/bjc.2016.45110.1038/bjc.2016.451 ↗
14. Yang Y, Gao X, Zhang M, et al. Novel Role of FBXW7 Circular RNA in Repressing Glioma Tumorigenesis. J Natl Cancer Inst. 2018;110(3)10.1093/jnci/djx166 ↗
15. 10.1016/j.canlet.2017.06.02710.1016/j.canlet.2017.06.027 ↗
16. 10.1038/s41388-018-0602-810.1038/s41388-018-0602-8 ↗
17. 10.1016/j.cell.2019.01.02510.1016/j.cell.2019.01.025 ↗
18. 10.1093/nar/gkx24710.1093/nar/gkx247 ↗
19. 10.1038/onc.2016.5210.1038/onc.2016.52 ↗
20. 10.1016/j.canlet.2016.12.03610.1016/j.canlet.2016.12.036 ↗
21. 10.15252/embr.20164358110.15252/embr.201643581 ↗
22. 10.1002/hep.2927010.1002/hep.29270 ↗
23. Liu Y, Dong Y, Zhao L, et al. Circular RNA‑MTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF4/Eg5 axis. Int J Oncol. 2018;53:1752–1762.
24. 10.1016/j.ijbiomac.2018.09.07610.1016/j.ijbiomac.2018.09.076 ↗
25. 10.1093/hmg/10.3.21110.1093/hmg/10.3.211 ↗
26. 10.1002/pros.2301610.1002/pros.23016 ↗
27. 10.1016/j.molcel.2014.08.01910.1016/j.molcel.2014.08.019 ↗
28. 10.18632/oncotarget.1275310.18632/oncotarget.12753 ↗
29. 10.1371/journal.pone.018459010.1371/journal.pone.0184590 ↗
30. 10.1016/j.cellsig.2010.07.01510.1016/j.cellsig.2010.07.015 ↗
31. 10.1016/j.ajhg.2010.10.00510.1016/j.ajhg.2010.10.005 ↗
32. 10.1158/0008-5472.CAN-06-157010.1158/0008-5472.CAN-06-1570 ↗
33. 10.1007/s11255-015-0915-210.1007/s11255-015-0915-2 ↗
34. 10.1016/j.molonc.2013.01.00310.1016/j.molonc.2013.01.003 ↗
35. 10.1177/101042831770551310.1177/1010428317705513 ↗
36. 10.1371/journal.pone.018763810.1371/journal.pone.0187638 ↗
37. 10.1038/modpathol.2016.15710.1038/modpathol.2016.157 ↗
38. 10.1038/nature0967710.1038/nature09677 ↗
39. 10.1002/pros.1036110.1002/pros.10361 ↗
40. Cao S, Sun R, Wang W, et al. RNA helicase DHX9 may be a therapeutic target in lung cancer and inhibited by enoxacin. Am J Transl Res. 2017;9:674–682.
41. 10.1158/0008-5472.CAN-18-223810.1158/0008-5472.CAN-18-2238 ↗
42. 10.1016/j.cell.2015.02.01410.1016/j.cell.2015.02.014 ↗
43. 10.18632/oncotarget.844610.18632/oncotarget.8446 ↗
44. 10.1038/sj.onc.120619510.1038/sj.onc.1206195 ↗
45. 10.1038/mtna.2016.2710.1038/mtna.2016.27 ↗
46. 10.1016/j.jhep.2018.01.01210.1016/j.jhep.2018.01.012 ↗
47. 10.18632/oncotarget.503310.18632/oncotarget.5033 ↗
48. 10.1016/j.bbrc.2017.07.16210.1016/j.bbrc.2017.07.162 ↗